Volume 4.06 | Feb 15

Prostate Cell News 4.06 February 15, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Proteolysis of Complement Factors iC3b and C5 by the Serine Protease Prostate-Specific Antigen in Prostatic Fluid and Seminal Plasma
Researchers used a mass spectrometry-based evaluation of prostatic fluid obtained from diseased prostates after removal by radical prostatectomy to identify potential immunoregulatory proteins. This analysis revealed the presence of Igs and the complement system proteins C3, factor B, and clusterin. [J Immunol] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)-DNA Adducts in Benign Prostate and Subsequent Risk for Prostate Cancer
Despite convincing evidence that PhIP – a heterocyclic amine generated by cooking meats at high temperatures – is carcinogenic in animal models, it remains unclear whether PhIP exposure leads to increased cancer risk in humans. PhIP-DNA adduct levels were measured in specimens from 534 prostate cancer case-control pairs nested within a historical cohort of men with histopathologically benign prostate specimens. [Int J Cancer] Abstract

Androgens Regulate TRAIL-Induced Cell Death in Prostate Cancer Cells via Multiple Mechanisms
To clarify the role of androgens on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in prostate cancer cells, scientists investigated the effects of androgen on TRAIL-induced cell death in a dose-response manner. [Cancer Lett] Abstract

Androgen Signaling Promotes Translation of TMEFF2 in Prostate Cancer Cells via Phosphorylation of the α Subunit of the Translation Initiation Factor 2
Scientists showed that translation of transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) is regulated by androgens. Addition of physiological concentrations of dihydrotestosterone to prostate cancer cell lines increases translation of endogenous TMEFF2 or transfected TMEFF2-Luciferase fusions, and this effect requires the presence of upstream open reading frames in the 5′-untranslated region of TMEFF2. [PLoS One] Full Article

Lumican Expression, Localization and Antitumor Activity in Prostate Cancer
Investigators analyzed the role of lumican in the pathogenesis of prostate cancer both in vivo and in vitro. Overall lumican up-regulation was observed in the primary tumors analyzed through both real-time PCR and immunostaining. [Exp Cell Res] Abstract

Expression and Role of the Angiotensin II AT2 Receptor in Human Prostate Tissue: In Search of a New Therapeutic Option for Prostate Cancer
Angiotensin II type 2 receptor (AT2R) and its AT2R-interacting protein expression were assessed on non-tumoral and tumoral human prostate using tissue microarray immunohistochemistry, binding assay, and Western blotting. AT2R’s effect on cell number was measured in primary cultures of epithelial cells from non-tumoral human prostate. [Prostate] Abstract

The Vav3 Oncogene Enhances the Malignant Potential of Prostate Cancer Cells under Chronic Hypoxia
The authors identified a key molecule, the Vav3 oncogene, and investigated the effects of Vav3 overexpression on cancer cell growth and malignant behavior and the possible apoptosis-inducing effect of Vav3 expression knockdown by small interfering ribonucleic acid in LNCaP cells under chronic hypoxia. [Urol Oncol] Abstract

Wild-Type p53 Suppresses the Epithelial-Mesenchymal Transition and Stemness in PC-3 Prostate Cancer Cells by Modulating miR-145
Scientists found that ectopic expression of wild-type p53 inhibited the migration and invasion, and enhanced the adhesion of p53-null PC-3 cells derived from prostate cancer bone metastasis. [Int J Oncol] Abstract

CLINICAL RESEARCH

Long-Term Prostate-Specific Antigen Velocity in Improved Classification of Prostate Cancer Risk and Mortality
It remains unclear whether adding long-term prostate-specific antigen velocity (PSAV) to baseline PSA values improves classification of prostate cancer (PCa) risk and mortality in the general population. Researchers examined whether long-term PSAV improves classification of PCa risk and mortality in the general population. [Eur Urol] Abstract

Laparoscopic versus Open Bilateral Intrafascial Nerve-Sparing Radical Prostatectomy after TUR-P for Incidental Prostate Cancer: Surgical Outcomes and Effect on Postoperative Urinary Continence and Sexual Potency
125 nerve-sparing laparoscopic radical prostatectomies and 128 nerve-sparing retropubic radical prostatectomies for incidental prostate cancer diagnosed after TUR-P were performed. Demographic data, peri- and postoperative measurements and functional outcomes were compared. [World J Urol] Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.

REVIEWS
Eph Receptors and Their Ligands: Promising Molecular Biomarkers and Therapeutic Targets in Prostate Cancer
This review briefly discusses the complex roles and biological mechanisms of action of these receptors and ligands and, with regard to prostate cancer, highlights their potential as biomarkers for both diagnosis and prognosis, their application as imaging agents, and current approaches to assessing them as therapeutic targets. [Biochim Biophys Acta] Abstract
INDUSTRY NEWS

U.S. FDA Grants Priority Review to Bayer’s Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
Bayer HealthCare announced that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer patients with bone metastases. [PR Newswire Association LLC] Press Release

North Shore-LIJ Awarded $300K Federal Grant for Prostate Cancer Research Training
The North Shore-LIJ Health System announced it has received a $300,000 grant from the US Department of Defense to train Hampton University undergraduates in research that will focus on the racial disparities in prostate cancer treatments, access to care and outcomes. [North Shore-LIJ Health Systems] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW American Society of Gene & Cell Therapy (ASGCT) 16th Annual Meeting
May 15-18, 2013
Salt Lake City, United States

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

PhD Studentship – Genome Mutation Data for the Clinical Management of Patients with Prostate Cancer (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)

Postdoctoral Position – Advanced Prostate Cancer (Weill Cornell Medical College)

Postdoctoral Position – The Role of ABC Transporter in Prostate Cancer (Queen Mary University London)

Postdoctoral Position – Aggressiveness or Progression in Prostate Cancer (Roswell Park Cancer Institute)


Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us